M Fumery1, D Duricova2,3, C Gower-Rousseau3,4,5, V Annese3,6, L Peyrin-Biroulet7, P L Lakatos3,8. 1. Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Université de Picardie Jules Verne, Amiens, France. 2. Department of Gastroenterology, Univerzity Karlovy, Prague, Czech Republic. 3. EPICOM, European Crohn & Colitis Organization, Vienna, Austria. 4. Public Health, Epidemiology and Economic Health, Epimad Registry, Maison Régionale de la Recherche Clinique, Centre Hospitalier Universitaire Régional, 59037, Lille Cedex, France. 5. Lille Inflammation Research International Center LIRIC - UMR 995 Inserm/Université Lille 2/CHRU de Lille, Equipe IBD and Environmental Factors: Epidemiology and Functional Analyses, Lille University, Lille, France. 6. Division of Gastroenterology, AOU Careggi Hospital, Florence, Italy. 7. Gastroenterology, Inserm U954, University Hospital of Nancy-Brabois, Université Henri Poincaré, Vandoeuvre-lès-Nancy, France. 8. 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Abstract
BACKGROUND: A better knowledge of the natural history of disabling chronic diseases is essential to improve patient management, evaluate the impact of treatment strategies and provide predictors for disabling disease and comprehensive information for patients. AIM: To summarise our current knowledge issued from population-based studies of the natural history of ulcerative colitis (UC) in children. METHODS: We searched MEDLINE (source PubMed) and international conference abstracts, and included all population-based studies that evaluated long-term outcome of paediatric-onset (<17 years at diagnosis) UC. RESULTS: A total of 26 population-based studies were considered in this review from the total of 61 articles or abstracts screened. Most patients presented disease extension and about two-thirds of patients had pancolitis at the end of follow-up. One-half of patients experienced extra-intestinal manifestations and primary sclerosing cholangitis was observed in 5-10% of patients. Overall, patients did not appear to have any significant growth retardation or delayed puberty. About two-thirds of patients required corticosteroid therapy and up to 25% were steroid dependent. An increased use of thiopurines was observed and the most recent data indicate that up to one-half of patients were exposed to thiopurines and 10-30% were exposed to anti-tumour necrosis factor. One-half of patients required hospitalisations and 20% of patients required colectomy after a follow-up of 10 years. CONCLUSIONS: Paediatric-onset UC is characterised by a high rate of disease extension. About 20% of patients had been operated at 10-year follow-up. New population-based studies are needed to evaluate the impact of new treatment strategies comprising immunosuppressants and biologics.
BACKGROUND: A better knowledge of the natural history of disabling chronic diseases is essential to improve patient management, evaluate the impact of treatment strategies and provide predictors for disabling disease and comprehensive information for patients. AIM: To summarise our current knowledge issued from population-based studies of the natural history of ulcerative colitis (UC) in children. METHODS: We searched MEDLINE (source PubMed) and international conference abstracts, and included all population-based studies that evaluated long-term outcome of paediatric-onset (<17 years at diagnosis) UC. RESULTS: A total of 26 population-based studies were considered in this review from the total of 61 articles or abstracts screened. Most patients presented disease extension and about two-thirds of patients had pancolitis at the end of follow-up. One-half of patients experienced extra-intestinal manifestations and primary sclerosing cholangitis was observed in 5-10% of patients. Overall, patients did not appear to have any significant growth retardation or delayed puberty. About two-thirds of patients required corticosteroid therapy and up to 25% were steroid dependent. An increased use of thiopurines was observed and the most recent data indicate that up to one-half of patients were exposed to thiopurines and 10-30% were exposed to anti-tumour necrosis factor. One-half of patients required hospitalisations and 20% of patients required colectomy after a follow-up of 10 years. CONCLUSIONS: Paediatric-onset UC is characterised by a high rate of disease extension. About 20% of patients had been operated at 10-year follow-up. New population-based studies are needed to evaluate the impact of new treatment strategies comprising immunosuppressants and biologics.
Authors: Alain M Schoepfer; Vu Dang Chau Tran; Jean-Benoit Rossel; Christiane Sokollik; Johannes Spalinger; Ekaterina Safroneeva; Thea von Graffenried; Sébastien Godat; Dieter Hahnloser; Stephan R Vavricka; Christian Braegger; Andreas Nydegger Journal: Inflamm Intest Dis Date: 2021-11-18
Authors: Ping Rao; Yong Zhou; Si-Qi Ge; An-Xin Wang; Xin-Wei Yu; Mohamed Ali Alzain; Andrea Katherine Veronica; Jing Qiu; Man-Shu Song; Jie Zhang; Hao Wang; Hong-Hong Fang; Qing Gao; You-Xin Wang; Wei Wang Journal: Int J Environ Res Public Health Date: 2016-08-30 Impact factor: 3.390
Authors: J B Wechsler; A Szabo; C L Hsu; R A Krier-Burris; H A Schroeder; M Y Wang; R G Carter; T E Velez; L M Aguiniga; J B Brown; M L Miller; B K Wershil; T A Barrett; P J Bryce Journal: Mucosal Immunol Date: 2018-01-24 Impact factor: 7.313